January 1, 2002Perfusion
The effects of platelet inhibitors on blood use in cardiac surgery
Why the study?
How should patients treated with GP IIb/IIIa receptor inhibitors be managed during urgent coronary artery bypass surgery to mitigate bleeding risk?
Population
Patients requiring coronary artery bypass surgery who have been treated with glycoprotein IIb/IIIa receptor…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide urgent CABG management on GP IIb/IIIa inhibitors; leaves open prospective validation.
Structured PICO
How should patients treated with GP IIb/IIIa receptor inhibitors be managed during urgent coronary artery bypass surgery to mitigate bleeding risk?
P
Population
Patients requiring coronary artery bypass surgery (CABG) who have been treated with glycoprotein (GP) IIb/IIIa receptor antagonists (abciximab, tirofiban, or eptifibatide)
I
Intervention
Perioperative management strategies including cessation of GP IIb/IIIa inhibitor, delay of surgery for up to 12 h, ultrafiltration via zero balance technique, standard heparin dosing, and as-needed platelet transfusion
O
Outcome
Bleeding risk and blood use during cardiac surgerysafety
Urgent CABG can be safely performed in patients on GP IIb/IIIa inhibitors by following specific perioperative management strategies to mitigate bleeding risk.
Cite This Study
Lee et al. (2002) studied this question.